Scholarlink

Background <p>Use of fluoroquinolones (FQs), broad-spectrum antibiotics, has been linked to adverse health outcomes and resulted in safety warnings by regulatory agencies worldwide. We tested the effect of Canadian risk mitigation measures (RMMs) introduced in January 2017 on FQ prescription rates.</p> Methods <p>We conducted a retrospective multi-site cohort study using administrative data from six Canadian provinces. The cohort included adults (18 + years) with outpatient prescriptions for four oral systemic FQs (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin) between 2008 and 2022. Overall FQ prescription rates and percentage of FQ prescriptions for three antibiotic indications (acute bacterial sinusitis [ABS], acute exacerbation of chronic obstructive pulmonary disease [AECOPD], urinary tract infection [UTI]) were assessed before and after RMMs were introduced. Segmented generalized linear models were applied to monthly prescription rates and percentages for: (1) pre-RMM (January 2008-December 2016; reference), (2) post-RMM pre-COVID (January 2017-Feburary 2020), and (3) post-RMM within-COVID (March 2020-December 2022) segments. We estimated province-specific relative rates (RR) for the post-RMM segments and slope coefficients for pre- and post-RMM segments and their 95% confidence intervals (CIs) and pooled them using random-effects models.</p> Results <p>Crude annual FQ prescription rates decreased from 107.5 to 45.0 per 1,000 population over the study period; in the pre-RMM segment, age- and sex-adjusted rates decreased an average of 0.30 per 1,000 population per month (95% CI: 0.19–0.41); province-specific estimates of decrease ranged from 0.16 to 0.48. The pooled RR for the post-RMM pre-COVID segment was 0.50 (95% CI: 0.43–0.59); the post-RMM within-COVID segment pooled RR was similar (RR = 0.38; 95% CI: 0.29–0.50). The decline in percentage of FQ prescriptions post-RMM pre-COVID was largest for UTI (pooled RR = 0.32, 95% CI: 0.25–0.41), followed by ABS (RR = 0.41, 95% CI: 0.34–0.51) and AECOPD (RR = 0.51, 95% CI: 0.37–0.69), although there was variation across provinces.</p> Conclusions <p>Canadian RMMs for FQ use were associated with a decrease in prescription rates overall and for three indications, although rates had begun to decline before RMMs were introduced and the magnitude of decrease varied across provinces. Safety warnings tailored to specific indications and regional practices may be needed to address variation in FQ prescribing.</p> Trial registration <p>HMA-EMA catalogue of real-world data studies (Study ID: 108,049).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of risk mitigation measures on oral fluoroquinolone prescribing: a multi-site population-based Canadian cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月25日

查看全文
  • Lisa M. Lix,
  • Matthew Dahl,
  • Audray St-Jean,
  • Hassan Maleki Golandouz,
  • Vicki Ling,
  • Donica Janzen,
  • Paul E. Ronksley,
  • Tayler Dawn Scory,
  • Daniel J. Dutton,
  • Devin Manning,
  • Greg Carney,
  • Christine Perras,
  • Pierre Ernst,
  • Robert W. Platt,
  • Samy Suissa,
  • Colin R. Dormuth,
  • Paul E. Ronksley,
  • Alan Katz,
  • J. Michael Paterson,
  • Kristian B. Filion,
  • Ingrid S. Sketris

摘要

Background

Use of fluoroquinolones (FQs), broad-spectrum antibiotics, has been linked to adverse health outcomes and resulted in safety warnings by regulatory agencies worldwide. We tested the effect of Canadian risk mitigation measures (RMMs) introduced in January 2017 on FQ prescription rates.

Methods

We conducted a retrospective multi-site cohort study using administrative data from six Canadian provinces. The cohort included adults (18 + years) with outpatient prescriptions for four oral systemic FQs (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin) between 2008 and 2022. Overall FQ prescription rates and percentage of FQ prescriptions for three antibiotic indications (acute bacterial sinusitis [ABS], acute exacerbation of chronic obstructive pulmonary disease [AECOPD], urinary tract infection [UTI]) were assessed before and after RMMs were introduced. Segmented generalized linear models were applied to monthly prescription rates and percentages for: (1) pre-RMM (January 2008-December 2016; reference), (2) post-RMM pre-COVID (January 2017-Feburary 2020), and (3) post-RMM within-COVID (March 2020-December 2022) segments. We estimated province-specific relative rates (RR) for the post-RMM segments and slope coefficients for pre- and post-RMM segments and their 95% confidence intervals (CIs) and pooled them using random-effects models.

Results

Crude annual FQ prescription rates decreased from 107.5 to 45.0 per 1,000 population over the study period; in the pre-RMM segment, age- and sex-adjusted rates decreased an average of 0.30 per 1,000 population per month (95% CI: 0.19–0.41); province-specific estimates of decrease ranged from 0.16 to 0.48. The pooled RR for the post-RMM pre-COVID segment was 0.50 (95% CI: 0.43–0.59); the post-RMM within-COVID segment pooled RR was similar (RR = 0.38; 95% CI: 0.29–0.50). The decline in percentage of FQ prescriptions post-RMM pre-COVID was largest for UTI (pooled RR = 0.32, 95% CI: 0.25–0.41), followed by ABS (RR = 0.41, 95% CI: 0.34–0.51) and AECOPD (RR = 0.51, 95% CI: 0.37–0.69), although there was variation across provinces.

Conclusions

Canadian RMMs for FQ use were associated with a decrease in prescription rates overall and for three indications, although rates had begun to decline before RMMs were introduced and the magnitude of decrease varied across provinces. Safety warnings tailored to specific indications and regional practices may be needed to address variation in FQ prescribing.

Trial registration

HMA-EMA catalogue of real-world data studies (Study ID: 108,049).